NCT05063565 2026-03-02
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT07154082 2025-09-04
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
Tongji Hospital
Phase 2 Recruiting
NCT04174781 2022-06-09
Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC
Zhejiang University
Phase 2 Unknown
NCT05240404 2022-02-15
Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
Xiangya Hospital of Central South University
Phase 2 Unknown
NCT04653389 2022-01-11
Perioperative Therapy for Hepatocellular Carcinoma
Zhejiang University
Phase 2 Terminated
NCT04981665 2022-01-05
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Zhejiang University
Phase 2 Unknown
NCT00610389 2010-05-10
Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Unknown